GZGuangyao Zhou

Guangyao Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guangyao Zhou has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Lianmin Zhang

    Department of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

    3 shared publications
  • Yijie Wang

    Department of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer Tianjin Medical University Cancer Institute and Hospital Tianjin China

    2 shared publications
  • Zhenfa Zhang

    Department of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

    2 shared publications
  • Chunnuan Wu

    Department of Pharmacy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, Tianjin, China

    1 shared publication
  • Jiaxiong Tan

    National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer Tianjin Medical University Cancer Institute and Hospital Tianjin China

    1 shared publication
  • Pengpeng Zhang

    Department of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer Tianjin Medical University Cancer Institute and Hospital Tianjin China

    1 shared publication

Latest Publications

  • Open Access

    Heterogeneity of Cancer‐Associated Fibroblasts and Precision Targeting Strategies for Cancer Therapy

    by Yijie Wang, Guangyao Zhou, Pengpeng Zhang, Zhenfa Zhang, Lianmin Zhang

    Immune checkpoint blockade (ICB) has transformed cancer therapy, but its effect is often limited by immunosuppression and resistance mechanisms within the tumor microenvironment (TME). Cancer‐associated fibroblasts (CAFs) represent a major stromal component of the TME. They exhibit substantial heterogeneity, dynamic plasticity, diverse cellular origins, and context‐dependent activation states, which critically determine the safety and efficacy of CAF‐targeted therapies. CAFs contribute to tumor immune evasion by remodeling the extracellular matrix, altering tissue mechanics and establishing structural barriers. In addition, CAFs release cytokines, chemokines, and exosomes to impair T‐cell trafficking and function. They also interact with immune and myeloid cells, further reducing the efficacy of ICB. Therefore, CAF‐targeted therapies are shifting from the strategy of extensive clearance to a more elaborate framework, which focuses on specific CAF subpopulations and their regulatory pathways, and combines specific strategies for subpopulations, functional reprogramming, and methods based on advanced delivery systems and diagnostic tools. Integrating spatial omics, single‐cell technologies, and 3D culture systems can help us better understand the different states of CAFs and how they are distributed in space. This enables the identification of targetable CAF states, informs reprogramming strategies, supports rational combination design, and facilitates biomarker discovery. This review emphasizes the heterogeneity and plasticity of CAFs in tumor immunosuppression, and advocates a conceptual shift from static cellular identity to a dynamic state–niche–function framework.

  • Open Access

    Integrating Single‐Cell Transcriptomics and Machine Learning to Define an ac4C Gene Signature in Lung Adenocarcinoma

    by Yuan Wang, Wei Su, Guangyao Zhou, Yijie Wang, Chunnuan Wu, Pengpeng Zhang, Lianmin Zhang

    Introduction: Lung adenocarcinoma, the most common subtype of non‐small cell lung cancer, faces challenges such as drug resistance and tumor heterogeneity. N4‐acetylcytidine (ac4C) is an important RNA modification involved in cancer progression, but its role in lung adenocarcinoma remains unclear.Methods: This study analyzed transcriptomic and single‐cell RNA sequencing data from public databases to investigate the expression and clinical significance of ac4C‐related genes in lung adenocarcinoma. Ten machine learning algorithms were applied to develop and validate an ac4C‐related gene signature (ARGSig) for prognosis prediction across multiple independent cohorts.Results: Cells with high ac4C activity showed increased intercellular communication and activation of tumor‐associated pathways. The ARGSig model effectively stratified patients by survival outcomes and predicted sensitivity to immune checkpoint inhibitors and chemotherapy agents.Conclusion: ac4C modification and its related genes play a critical role in lung adenocarcinoma development. The ARGSig model provides a promising molecular tool for prognosis evaluation and personalized treatment guidance in lung adenocarcinoma patients.


  • Open Access

    Mechanistic Insights and Therapeutic Potentials of Ubiquitin‐Proteasome System in Non‐Small Cell Lung Cancer

    by Guangyao Zhou, Jiaxiong Tan, Pengpeng Zhang, Zhaokai Zhou, Lianmin Zhang, Zhenfa Zhang

    Non‐small cell lung cancer (NSCLC) remains a leading cause of cancer mortality. Despite advancements in gene targeted therapies and immunotherapies, high heterogeneity contributes to limited efficacy and therapeutic resistance. Ubiquitination, a crucial post‐translational modification that regulates protein stability and degradation, plays a significant role in cancer pathogenesis by influencing key oncogenic pathways and tumour progression. This review systematically explores the ubiquitin‐proteasome system (UPS) and its potential as a therapeutic target for NSCLC. We highlight recent preclinical and clinical studies focusing on ubiquitination‐related biomarkers, drug targets and emerging therapies like proteasome inhibitors and Proteolysis‐targeting chimeras (PROTACs). By exploring the impact of the UPS on tumour biology, the progression of NSCLC and its response to therapy, we aim to underscore the potential of targeting the ubiquitination‐deubiquitination system as a complementary or synergistic approach to existing therapeutic strategies in NSCLC, thereby enhancing patient outcomes and overcoming treatment resistance.